August 12, 2021
AbbVie Ventures Launches Inaugural AIM Award

AbbVie Ventures is excited to announce the launch of its inaugural AbbVie Innovation Midwest (AIM) Award, an incubator program designed to enable emerging scientists, researchers and biotech entrepreneurs working on novel science with potential for transformational therapies.  
The AIM Award is an investment by AbbVie to catalyze a thriving biotech ecosystem in its backyard – the Midwest. The region has much of the raw materials needed for success, including well-respected research institutions and scientists. To date, however, this potential has been limited by a lack of early-stage financing and skilled management.  
AbbVie will grant AIM awards for up to two early-stage biotech companies. Each AIM award includes the opportunity to receive seed funding from AbbVie Ventures, as well as a one-year residence in the Portal Innovations facility located in Chicago’s Fulton Market.
Please send your application to by 11:59pm ET on September 3, 2021.
For more information on how to apply, please visit AbbVie Ventures.
Media inquiries:
Vusi Moyo
Call: 847-937-4319



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?